Embed Size (px)
Citation preview
1
AcuFocus
Y a r i L . M i t c h e l l
C h i e f B u s i n e s s D e v e l o p m e n t O f f i c e r
The IC-8® Small Aperture IOL
The IC-8 IOL combines the principle of small aperture optics with a high quality aspheric
monofocal lens platform to deliver the first implantable small aperture intraocular lens
Hydrophobic acrylic
UV-blocking
12.5 mm overall length
6.00 mm optic diameter
Polyvinylidene fluoride
Carbon nano-particles
1.36 mm aperture
3.23 mm total diameter
2
AcuFocus’ Measured Approach
From Concept to Commercialization
L I M I T E D
R E L E A S E
Began with limited product
release in select markets and
surgeons across Europe and
Asia-Pacific in 2016.
C L I N I C A L
E VA L U AT I O N
Six prospective international
studies evaluating lens
performance in normal and
irregular cornea patients
starting in 2012.
U S M A R K E T
E N T R Y
Initiated clinical trial in
November 2018. Anticipated
US market entry
Q4 2020/ Q1 2021.
F O C U S E D
G R O W T H
Expanded commercialization
in Australia in 2018 resulting in
50%+ year over year growth in
accounts and 100%+ growth
in implants.
P R O C E D U R E
R E F I N E M E N T
Patient selection and
application refined through
continuous review of
commercial outcomes.
3
IC-8® IOL SHARE Study4
General and
Refractive
Practice
Southport, QLD
Pure Refractive
Practice
Sydney, NSW
Corneal Specialist
Practice
Melbourne, VIC
Cataract and Retinal
Specialist Practice
Launceston, TAS
General, Cataract
and Refractive
Practice
Melbourne, VIC
Anterior Segment
Specialist Practice
Melbourne, VIC
General, Pediatric
and Glaucoma
Specialist
Perth, WA
• Study Purpose: To assess IC-8 IOL utilization potential and current penetration in varying practice types across Australia
• Account Selection: Accounts selected based on size of overall cataract business, type of practice and experience with the IC-8 IOL
• 11% (7/ 63) accounts selected to participate
• Data captured on all patients treated in a consecutive 3 month period:
• Implants performed between:
• June – August 2018, or
• January - March 2019
• 1146 IOL surgeries
• 573 patients
Surgeon Monofocal IOLsMonofocal
Toric IOLsPC-IOLs PC-IOL Toric IC-8 IOL
IC-8 IOL
Segment Utilization
Surgeon 1 21.6% 13.7% 17.6% 25.5% 21.6%Irregular Cornea,
PC-IOL Patients
Surgeon 2 0.0% 47.6% 33.6% 4.9% 14.0%Irregular Cornea,
Advanced Monovision
Surgeon 3 66.2% 8.5% 12.3% 3.8% 9.2%Irregular Cornea,
Low Myopia
Surgeon 4 29.4% 25.8% 18.6% 19.1% 7.2%Irregular Cornea,
Advanced Monovision
Surgeon 5 31.8% 20.0% 23.5% 20.0% 4.7%Irregular Cornea,
Advanced Monovision
Surgeon 6 35.3% 58.8% 1.5% 0.0% 4.4%Irregular Cornea,
Advanced Monovision
Surgeon 7 73.8% 23.5% 0.0% 0.0% 2.7% Irregular Cornea
IC-8® IOL SHARE Study: IOL Mix by Surgeon5
31.6% AVERAGE
PC-IOL UTILIZATION
68.4% AVERAGE
MONOFOCAL IOL
UTILIZATION
All surgeons, despite practice type and IOL mix, have a place for the IC-8 IOL in their practice
6
N=888 eyes, 573 patients
IC-8® IOL SHARE Study:
IOL Utilization by Type and Manufacturer
8% of all eyes, 11% of all patients,
presenting for surgery received the IC-8® IOL
AcuFocus is the 6th most utilized lens
manufacturer for all IOLs
23.2%
15.5%
14.2%
13.6%
8.8%
8.0%
7.0%
2.7%2.7%
2.5%1.5%
0.3%
IOL Utilization by Manufacturer
1- J&J Vision
2 - Medicontur
3 - MBI
4 - Zeiss
5 - Alcon
6 - AcuFocus
7 - PhysIOL
38.2%
30.2%
14.8%
8.9%
8.0%
IOL Lens Type Distribution
Monofocal Monofocal Toric PC-IOL
PC-IOL Toric IC-8 IOL
84.4%
2.3%
8.9%2.9% 1.5%
0%
20%
40%
60%
80%
100%
Normal Eye Naturally Occuring
Corneal Irregularity
Corneal Pathology Prior Corneal
Surgery
Both*
Corneal Status by Eye
IC-8® IOL SHARE Study:
Distribution of Regular and Irregular Corneas
7
N=910
*Eyes with a history of both corneal pathology and corneal surgery
15.6% of eyes
presented with
irregular cornea
18.7% of all patients
presenting for lens
surgery had at least one
irregular cornea eye
41.9%
26.5%
16.9%
2.2% 0.7% 2.2% 1.5%5.9%
2.2%
0%
20%
40%
60%
80%
100%
Monofocal Monofocal Toric IC-8 IOL Bifocal Bifocal Toric EDOF EDOF Toric Trifocal Trifocal Toric
IOL Type for Irregular Cornea Eyes
IC-8® IOL SHARE Study:
IC-8 IOL Takes Share In Irregular Cornea
8
N=136 eyes, N=107 patients
16.9% of irregular cornea eyes received an IC-8 IOL.
20.6% of irregular cornea patients received an IC-8 IOL.
IC-8® IOL SHARE Study:
IC-8 IOL Takes Share in PC-IOL Segment
9
N=281
The IC-8® IOL is the single
MOST UTILIZED PC-IOL LENS model
25.3%
22.1%
18.9%
13.2%
8.5%
7.8%4.3%
PC-IOL by Manufacturer
AcuFocus PhysIOL Zeiss Medicontour
Oculentis Alcon J&J Vision
Small aperture method of action is the 2nd
most utilized PC-IOL type at 25.3% OF ALL
PC-IOLs implanted including toric models
40.6%
25.3%
23.1%
11.0%
PC-IOL Utilization by Type
TrifocalBifocal
IC-8 IOL
EDOF
IC-8® IOL SHARE Study:
IC-8 IOL Takes Share and Grows the Premium Segment
10
N=43
20.2% of all normal eyes receiving a
PC-IOL, including toric models,
received an IC-8 IOL
43.3%
20.2%
25.6%
10.9%
PC-IOL Type - Normal Cornea
Eyes
TrifocalBifocal
IC-8 IOL
EDOF
N=238
53.5% of all irregular cornea eyes
receiving a PC-IOL, including toric,
received an IC-8 IOL
25.6%
53.5%
9.3%
11.6%
PC-IOL Type - Irregular Cornea
EyesTrifocal
Bifocal
IC-8 IOL
EDOF
IC-8® IOL SHARE Study:
IC-8 IOL Implantation Strategy
11
Irregular Cornea
Normal Cornea
N=63
69%
31%
Patient Type
The surgeons involved in this analysis use
the IC-8 IOL in both normal AND irregular
cornea patients
87.3%
12.7%
Implant Strategy
While the majority of patients receive the IC-8
IOL in one eye. Bilateral implantation was
used in 12.7% of patients.
Binocular
Monocular
IC-8® IOL:
Taking Share & Growing the Premium Channel
12
11% 8.7%
Percent of eyes with < 1.50 D of pre-op corneal
astigmatism receiving an
IC-8 IOL
25.3%16.9%
Percent of all
patients treated
with an IOL
received an
IC-8 IOL
Percent of
irregular cornea
eyes that were
treated with an
IC-8 IOL
Percent of all
eyes treated
with a PC-IOL
that received an
IC-8 IOL
MOST UTILIZED
PC-IOL LENS
PLATFORM
#1
13
Thank you!
